The Hindu Business Line, 9 June 2020:

Joining the list of drugs repurposed for Covid-19, a sepsis drug from Bharat Serums and Vaccines is getting into Phase III clinical trials. The Mumbai based biopharmaceutical firm has got approval from the drug regulator to start trails on the injectable drug that it sells under the brand U-Tryp. BSVL Managing Director and Chief Executive Officer said the company had approached the regulator two months back for the drug Ulinastatin. It got approval for clinical trails on patients to see if it works on Covid-19 patients with acute respiratory distress syndrome (ARDS).

Read more: https://www.thehindubusinessline.com/economy/bharat-serums-to-test-sepsis-drug-to-treat-respiratory-distress-among-covid-patients/article31780832.ece

About BSV

BSV has been a pioneer in the development of blood components and therapeutic antibody products for infectious and non-infectious diseases. For over four decades, BSVL has focused on utilizing its scientific resources to develop several biological, biotechnology and pharmaceutical products to treat various types of diseases, contributing to preserve, protect and enhance the quality of life. We aim to be a leading biopharmaceutical company driven by people & science to set benchmarks in patient outcomes in Women’s Health, Critical Care & Emergency Medicine.

For more information, please contact:

Irawati Gowariker, BSV, Irawati.gowariker@bsvgroup.com